THC Tenet Healthcare Corporation

EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Tenet Healthcare Corp. - THC

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Tenet Healthcare Corp. (NYSE:THC) resulting from allegations that Tenet may have issued materially misleading business information to the investing public.

On October 3, 2016, Tenet disclosed that it would pay states and the federal government $514 million to settle allegations that its hospitals in Georgia and South Carolina paid kickbacks for obstetric referrals. Under the settlement, two Tenet subsidiaries will plead guilty to one count of conspiracy to violate federal kickback laws. On this news, shares of Tenet fell $0.91 per share or over 4% to close at $21.57 per share on October 3, 2016.

Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Tenet investors. If you purchased shares of Tenet on or before October 3, 2016, please visit the firm’s website at http://www.rosenlegal.com/cases-963.html for more information. You may also contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.

Attorney Advertising. Prior results do not guarantee a similar outcome.

EN
04/10/2016

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Tenet Healthcare Corporation

Tenet Healthcare Corp: 1 director

A director at Tenet Healthcare Corp sold 2,178 shares at 197.470USD and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Magnificent Seven's Turn to Shine We remain near-term bullish since our 4/22/25 Compass, and our intermediate-term outlook remains bullish as well (as of our 5/14/25 Compass). We will maintain our bullish intermediate-term outlook as long as market dynamics remain healthy and the S&P 500 (SPX) is above 6200 (up from 6028-6059). Additionally, we discussed since our 10/14/25 Compass how our near-term bullish outlook remains intact as long as the SPX holds above 6550-6569, which coincided with the ...

Moody's Ratings assigns Ba3 and B2 ratings to Tenet Healthcare's propo...

Moody's Ratings (Moody's) assigned Ba3 rating to Tenet Healthcare Corporation's ("Tenet") proposed offering of senior secured first lien notes due 2032 and B2 rating to the senior unsecured notes proposed offering due 2033. Tenet intends to use the net proceeds from this offering for general corpora...

Tenet Healthcare Corporation: Update to credit analysis

Our credit view of this issuer reflects its considerable scale and its very good liquidity and favorable debt maturity profile, offset by its moderately high financial leverage.

Moody's Ratings affirms Tenet Healthcare Corporation's Ba3 CFR; revis...

Moody's Ratings (Moody's) affirmed the ratings of Tenet Healthcare Corporation ("Tenet") including the Ba3 Corporate Family Rating (CFR), Ba3-PD Probability of Default Rating (PDR), Ba3 ratings of senior secured first and second lien notes and B2 rating of senior unsecured notes. At the same time, w...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch